Many companies are trying to find the next Eric Lefkofsky, but Eric already found his company. Eric Lefofksy founded Tempus almost two years ago with a few other doctors and scientists. His $200 million investment in Tempus was finally approved by the FDA on December 8th, 2016. The approval of Tempus has raised hopes for patients suffering from debilitating chronic diseases like Parkinson’s disease and congestive heart failure.
Doctors have been looking for a way to better diagnose an array of chronic diseases that plague the U.S. healthcare system, so Tempus is positioned well to take advantage of this huge market opportunity. Under the leadership of Eric Lefkofsky, Tempus’s first product uses blood tests and machine learning technology to identify cancer cells in patients who have been treated with chemotherapy.
The results will give doctors a better understanding of whether the cancer has been eradicated from the patient’s system. Its a whole medical innovation that will benefit all in the mid and longterm. The U.S. spends roughly $80 billion per year on cancer treatments, so Tempus could be very profitable once it is fully rolled out. As Eric Lefkofsky states, Tempus also has several other products in the pipeline that help doctors diagnose and treat even more diseases, including autoimmune conditions like rheumatoid arthritis.
Just recently, Eric Lefkofsky announced the future projects for the medical firm. The market for Tempus’s products is expected to grow into trillions of dollars per year in the next few years, so this high-growth company could be very valuable once it goes public. Eric Lefkofsky continues to make smart moves as he helps lead his company Tempus to a successful IPO. When Tempus was finally approved by the FDA, it raised hope for patients suffering from chronic diseases like Parkinson’s disease and congestive heart failure.